Literature DB >> 31113593

Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity.

Fernando Martínez-Valle1, Mar Riveiro-Barciela2, María-Teresa Salcedo3, Xavier Merino-Casabiel4, Andreu Fernández-Codina5, Inés de Torres3, Rafael Esteban2, María Buti2.   

Abstract

IgG4-related disease is a recently-described fibro-inflammatory condition with characteristic histopathological findings in the organs involved. The most commonly affected organs are pancreas, lymph nodes, and retroperitoneum. Liver disease usually involves bile structures and therefore IgG4-related disease is considered a cause of secondary sclerosing cholangitis. One out of three patients with IgG4 sclerosing cholangitis also presents autoimmune pancreatitis, although it can be associated with manifestations in other organs. One of the main features of IgG4-related disease is its good prognosis due to the great response to glucocorticoid therapy. However, relapse of the disease is not uncommon, especially when steroid therapy is decreased or stopped. Rituximab seems to be an effective treatment to achieve remission of the disease. We report the case of a 74 year-old man diagnosed with IgG4-related disease based on increase of serum IgG4 levels, imaging and histopathological findings, with systemic involvement including sclerosing cholangitis. Despite the absence of liver fibrosis at onset, the early use of glucocorticoids and rituximab therapy, the patient presented clinical and analytical deterioration, leading to secondary biliary cirrhosis. In conclusion, this clinical case highlights the importance of prompt diagnosis and therapeutics for sclerosing cholangitis secondary to IgG4-related disease in order to avoid progression of the disease and development of liver cirrhosis, as well as the refractory, aggressive nature of the disease in some cases as this one.
Copyright © 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Case report; IgG4-related disease; Liver cirrhosis; Rituximab; Secondary cholangitis

Mesh:

Substances:

Year:  2019        PMID: 31113593     DOI: 10.5604/01.3001.0012.7916

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  2 in total

1.  Immunoglobulin G subtypes-1 and 2 differentiate immunoglobulin G4-associated sclerosing cholangitis from primary sclerosing cholangitis.

Authors:  Miroslav Vujasinovic; Pia Maier; Hartwig Maetzel; Roberto Valente; Raffaella Pozzi-Mucelli; Carlos F Moro; Stephan L Haas; Karouk Said; Caroline S Verbeke; Patrick Maisonneuve; J-Matthias Löhr
Journal:  United European Gastroenterol J       Date:  2020-04-29       Impact factor: 4.623

2.  Immunoglobulin G4-Associated Cholangitis: Two Case Reports and Clinical Use of Classic and Emerging International Diagnostic Criteria.

Authors:  Ricardo Jacaranda de Faria; Marcos Vasconcelos Carneiro; Lucio Lucas Pereira; Raissa Dytz; Gabriela Dos Santos
Journal:  J Med Cases       Date:  2022-03-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.